Nephros, Inc. · NASDAQ:NEPH
Nephros — Shareholder Meeting (May 2007)
16 slides from Nephros's shareholder meeting presentation, May 22, 2007
Slide 1: NEPHROS, INC. 2007 Annual Stockholders Meeting
Exhibit 99.1 NEPHROS, INC. 2007 Annual Stockholders Meeting May 22, 2007
Slide 2: Forward Looking Statements
NEP: Forward Looking Statements This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements may include statements regarding the efficacy and intended use of Nephros' technologies, the timelin
Slide 3: Risk Factors
Risk Factors Factors that may cause such differences include the risks that: (i) products that appeared promising to Nephros in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials; (ii) Nephros may not obtain appr
Slide 4: The Nephros Mission
The Nephros Mission To offer technology with key and marketable advantages in both the blood and water filtration domains: ▪ Unsurpassed, Demonstrated Product Efficacy ▪ User-friendly product designs responding to critical market needs and offering unique, measurable performance advantages ▪ Favorab
Slide 5: Achievements in 2006
Achievements in 2006 • Continuing to increase filter penetration in Europe for use on existing HDF machines; in use in over 50 clinics in 12 countries • Nephros Selected for Development of Dual Stage Ultra Reliable Portable Personal Water Filtration by U.S. Marine Corps [Graphics Omitted]
Slide 6: Achievements in 2006
Achievements in 2006 Important and valuable results from our European clinical trials: » Multi-Center Study Concludes Nephros’ Mid-Dilution Hemodiafiltration Therapy Achieves Higher Clearance of Low Molecular Weight Proteins (Oct) » Nephros Announces Positive Results of Clinical Study for OLpūr MD19
Slide 7: Research and Development Progress
Research and Development Progress • Completed engineering on our OLpūr H2H add-on clinical module. Modules are ready for clinical trials. • Progressing with an established dialysis machine manufacturer to develop our stand-alone HDF machine Ø Prototype build in process; initial product expected to d
Slide 8: What has happened since year-end?
What has happened since year-end? • Received FDA approval to initiate our U.S. clinical trial on the OLpūr H2H Module and MD220 filter • Completed our IRB approvals; completed 2 of our 3 clinical contracts • Clinical trial training phase is set to begin at our first New York clinic
Slide 9: What has happened since year-end?
What has happened since year-end? • Completed a new agreement with our primary European distributor, ensuring year-on-year European sales growth. Now cash-flow positive on European operations • Initiated water filtration product development collaboration with CamelBak Products, LLC, a notable milita
Slide 10: Market forces are driving adoption of more effective therapies, and HDF in particular
Market forces are driving to adoption of more effective therapies, and HDF in particular: A Major GAO Report issued in November 2006 calls for bundling of Dialysis therapy and drug expenses. This provides a driver toward improved ESRD therapies to reduce medication requirements. [Graphics Omitted]
Slide 11: Market forces are driving adoption of more effective therapies, and HDF in particular
Market forces are driving to adoption of more effective therapies, and HDF in particular: Since November 2006, a series of reports in The New York Times, The Wall Street Journal, MarketWatch, and other publications in the U.S. and abroad are calling into question the safety of Epoiten (anemia medica
Slide 12: Market forces are driving adoption of more effective therapies, and HDF in particular
Market forces are driving to adoption of more effective therapies, and HDF in particular: Patient population growth is currently averaging 6% per year in the U.S.; a demonstrated 35% reduction in mortality risk with HDF can dramatically accelerate growth of the clinical “customer base”: [Graphics Om
Slide 13: Nephros Strategy: ESRD Therapy
Nephros Strategy: ESRD Therapy • Continue to showcase product efficacy in our target markets, drawing on our positive clinical data • Convert existing hemodialysis machines at the major clinical providers to hemodiafiltration with our OLpūr H2H technology; currently working on alliances with major c
Slide 14: Driving Forces on Water Quality
Driving Forces on Water Quality • A 2004 Study showed that 14 of 20 major U.S. hospitals across 14 states tested positive for legionella in the water supply. • CDC estimates up to 18,000 U.S. cases of Legionnaire’s Disease annually; 23% of reported cases occurring in hospitals; in-hospital Legionnai
Slide 15: Nephros Strategy: Water Filtration
Nephros Strategy: Water Filtration • Entering the U.S. market now, and exploring opportunities in Europe; opportunities are global • Initiated a multi-hospital study to demonstrate our DSU product effectiveness in stopping legionella bacterium; targeted for publication this year. • Currently initiat
Slide 16: NEPHROS, INC. The Future of ESRD Therapy
NEPHROS, INC. The Future of ESRD Therapy